COMPANY
Clinical Phase 2
Keywords: oncology infectious disease infectious diseases cancer COVID-19 Covid19 NP-101 TQ Formula/Tab
Location: Pearland, TX · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 2: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. source ↗
- Trial start Phase 2: To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05785390 | Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. | Phase 2 | Terminated | Feb 22, 2023 | May 9, 2025 (actual) |
| NCT04914377 | To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants | Phase 2 | Completed | Jun 8, 2021 | Dec 16, 2021 (actual) |